NEUP
Neuphoria Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$23M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisNEUP
BIIB
Try popular comparisons:
Stock Comparison
NEUP vs BIIB
Revenue, margins, valuation, and 5-year total return — side by side.
BIIB
Biogen Inc.
Drug Manufacturers - General
Market Cap$29.02B
5Y Perf.-18.1%
NEUP vs BIIB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NEUP |  BIIB |
|---|---|---|
| Industry | Medical - Pharmaceuticals | Drug Manufacturers - General |
| Market Cap | $23M | $29.02B |
| Revenue (TTM) | $-10M | $9.86B |
| Net Income (TTM) | $-28M | $1.37B |
| Gross Margin | 100.0% | 69.8% |
| Operating Margin | -7.2% | 15.6% |
| Forward P/E | — | 13.5x |
| Total Debt | $226K | $6.95B |
| Cash & Equiv. | $22M | $3.01B |
NEUP vs BIIB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NEUP
BIIB
| Stock | Dec 21 | Jun 26 | Return |
|---|---|---|---|
| Neuphoria Therapeut… (NEUP) | 100 | 2.9 | -97.1% |
| Biogen Inc. (BIIB) | 100 | 81.9 | -18.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEUP vs BIIB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIIB leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Neuphoria Therapeutics Inc. is the stronger pick specifically for valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
🥇BIIB emerged as the overall leader. Track its performance:
NEUP
Neuphoria Therapeutics Inc.
The Defensive Pick
NEUP is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.38, Low D/E 0.8%, current ratio 3.56x
- Better valuation composite
Best for: sleep-well-at-night
BIIB
Biogen Inc.
The Income Pick
BIIB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.34
- Rev growth 1.4%, EPS growth -21.1%, 3Y rev CAGR -1.2%
- -17.2% 10Y total return vs NEUP's -97.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  BIIB | 1.4% revenue growth vs NEUP's -140.1% |
| Value |  NEUP | Better valuation composite |
| Quality / Margins | BIIB | 13.9% margin vs NEUP's -2.4% |
| Stability / Safety | BIIB | Beta 0.34 vs NEUP's 1.38 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIIB | +55.4% vs NEUP's -34.9% |
| Efficiency (ROA) | BIIB | 4.7% ROA vs NEUP's -77.5%, ROIC 6.5% vs -13.4% |
NEUP vs BIIB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
NEUP vs BIIB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBIIBLAGGINGNEUP
NEUPNeuphoria Therapeutic…
1leads
BIIBBiogen Inc.
3leads
6 Total Categories
CATEGORYLEADERvs NEUPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BIIB4/6
Valuation MetricsMultiples, price ratios, and targets
NEUP4/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
BIIB5/6
Risk & VolatilityBeta, volatility, and downside exposure
BIIB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BIIB leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIIB and NEUP operate at a comparable scale, with $9.9B and -$10M in trailing revenue. BIIB is the more profitable business, keeping 13.9% of every revenue dollar as net income compared to NEUP's -2.4%. On growth, BIIB holds the edge at +1.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| RevenueTrailing 12 months | -$10M | $9.9B |
| EBITDAEarnings before interest/tax | -$25M | $2.4B |
| Net IncomeAfter-tax profit | -$28M | $1.4B |
| Free Cash FlowCash after capex | $59M | $2.6B |
| Gross MarginGross profit ÷ Revenue | +100.0% | +69.8% |
| Operating MarginEBIT ÷ Revenue | -7.2% | +15.6% |
| Net MarginNet income ÷ Revenue | -2.4% | +13.9% |
| FCF MarginFCF ÷ Revenue | +4.9% | +26.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -101.4% | +31.1% |
BIIB leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
NEUP leads this category, winning 4 of 4 comparable metrics.
Valuation Metrics
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| Market CapShares × price | $23M | $29.0B |
| Enterprise ValueMkt cap + debt − cash | $2M | $33.0B |
| Trailing P/EPrice ÷ TTM EPS | -18.74x | 22.26x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.51x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 11.72x |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 2.96x |
| Price / BookPrice ÷ Book value/share | 0.24x | 1.58x |
| Price / FCFMarket cap ÷ FCF | 0.30x | 14.15x |
NEUP leads this category, winning 4 of 4 comparable metrics.
Profitability & Efficiency
Evenly matched — NEUP and BIIB each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
BIIB delivers a 7.5% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $-110 for NEUP. NEUP carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to BIIB's 0.38x. On the Piotroski fundamental quality scale (0–9), NEUP scores 8/9 vs BIIB's 5/9, reflecting strong financial health.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -109.7% | +7.5% |
| ROA (TTM)Return on assets | -77.5% | +4.7% |
| ROICReturn on invested capital | -13.4% | +6.5% |
| ROCEReturn on capital employed | -3.7% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.38x |
| Net DebtTotal debt minus cash | -$21M | $3.9B |
| Cash & Equiv.Liquid assets | $22M | $3.0B |
| Total DebtShort + long-term debt | $226,487 | $6.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 6.91x |
Evenly matched — NEUP and BIIB each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
BIIB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BIIB five years ago would be worth $5,061 today (with dividends reinvested), compared to $244 for NEUP. Over the past 12 months, BIIB leads with a +55.4% total return vs NEUP's -34.9%. The 3-year compound annual growth rate (CAGR) favors BIIB at -12.5% vs NEUP's -47.9% — a key indicator of consistent wealth creation.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +12.8% | +10.5% |
| 1-Year ReturnPast 12 months | -34.9% | +55.4% |
| 3-Year ReturnCumulative with dividends | -85.8% | -33.1% |
| 5-Year ReturnCumulative with dividends | -97.6% | -49.4% |
| 10-Year ReturnCumulative with dividends | -97.6% | -17.2% |
| CAGR (3Y)Annualised 3-year return | -47.9% | -12.5% |
BIIB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
BIIB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BIIB is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than NEUP's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BIIB currently trades 95.4% from its 52-week high vs NEUP's 20.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 0.34x |
| 52-Week HighHighest price in past year | $21.40 | $205.97 |
| 52-Week LowLowest price in past year | $3.65 | $121.05 |
| % of 52W HighCurrent price vs 52-week peak | +20.1% | +95.4% |
| RSI (14)Momentum oscillator 0–100 | 36.3 | 55.2 |
| Avg Volume (50D)Average daily shares traded | 48K | 1.0M |
BIIB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $218.32 |
| # AnalystsCovering analysts | — | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BIIB leads in 3 of 6 categories (Income & Cash Flow, Total Returns). NEUP leads in 1 (Valuation Metrics). 1 tied.
Best OverallBiogen Inc. (BIIB)Leads 3 of 6 categories
Loading custom metrics...
NEUP vs BIIB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NEUP or BIIB a better buy right now?
Biogen Inc.
(BIIB) offers the better valuation at 22. 3x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NEUP or BIIB?
Over the past 5 years, Biogen Inc.
(BIIB) delivered a total return of -49. 4%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: BIIB returned -17. 2% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NEUP or BIIB?
By beta (market sensitivity over 5 years), Biogen Inc.
(BIIB) is the lower-risk stock at 0. 34β versus Neuphoria Therapeutics Inc. 's 1. 38β — meaning NEUP is approximately 302% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Neuphoria Therapeutics Inc. (NEUP) carries a lower debt/equity ratio of 1% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — NEUP or BIIB?
On earnings-per-share growth, the picture is similar: Biogen Inc.
grew EPS -21. 1% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NEUP or BIIB?
Biogen Inc.
(BIIB) is the more profitable company, earning 13. 2% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 13. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIIB leads at 19. 1% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NEUP or BIIB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NEUP or BIIB better for a retirement portfolio?
For long-horizon retirement investors, Biogen Inc.
(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34)). Both have compounded well over 10 years (BIIB: -17. 2%, NEUP: -97. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NEUP and BIIB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.